Aptose Biosciences, Inc. (APTO)
| Market Cap | 395.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -48.23M |
| Shares Out | 85.86M |
| EPS (ttm) | -0.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $4.40 |
| Previous Close | $4.39 |
| Change ($) | 0.01 |
| Change (%) | 0.23% |
| Day's Open | 4.39 |
| Day's Range | 4.33 - 4.52 |
| Day's Volume | 709,033 |
| 52-Week Range | 4.03 - 9.00 |
Aptose Biosciences (APTO) has been struggling lately, but the selling pressure may be coming to an end soon.
Aptose shares are weak in post-ASH trading as the Phase I CG-806 study has yet to produce a clinical response in B-cell malignancies. Three B-cell patients did see some tumor reduction at lowe...
SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, Dec...
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
Aptose (APTO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers
Aptose Biosciences and Five Prime Therapeutics both have explosive growth potential.
Aptose shares have been weak of late, but there have been no negative updates to the company's core clinical programs, and management recently started its third trial (CG-806 in AML). It is un...
Aptose Biosciences' (APTO) CEO William Rice on Q3 2020 Results - Earnings Call Transcript
Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level
Abstracts Accepted for Presentation Abstracts Accepted for Presentation
SAN DIEGO and TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target th...
Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.
Phase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg Phase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg
SAN DIEGO and TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target...
SAN DIEGO and TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target...
Aptose Biosciences (APTO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
APTO's lead candidate, CG-806, is due for important updates in 4Q2020.
SAN DIEGO and TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting th...
Aptose has recently raised more cash, and looks set for its foreseeable clinical trial needs.
Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2020 Results - Earnings Call Transcript
SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target ...
SAN DIEGO and TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that it has commenced an underwritten pu...
Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML
Can the run for Sarepta Therapeutics, Viela Bio, and Aptose Biosciences continue?
Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies
SAN DIEGO and TORONTO, June 02, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiat...
Aptose Biosciences' (APTO) CEO William Rice on Q1 2020 Results - Earnings Call Transcript
SAN DIEGO and TORONTO, May 05, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiate...
Data from patients at first two dose levels; Phase 1a/b study is ongoing Data from patients at first two dose levels; Phase 1a/b study is ongoing
Aptose Riding Higher As The Street Starts Paying Attention
Aptose Biosciences Inc. (APTO) CEO William Rice on Q4 2019 Results - Earnings Call Transcript
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
Investing in this emerging cancer-focused biotech may just allow you to retire early.
Top Ranked Momentum Stocks to Buy for January 29th
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
SAN DIEGO and TORONTO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced...
Investors excited about the biotech's prospects are taking the opportunity to buy on the dip following the announcement of a new stock offering.
Promising preclinical data and the acquisition of another small biotech continued to generate enthusiasm among investors.
SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics t...
Aptose Management and KOL’s Discuss Early Clinical Observations with CG-806 and APTO-253 Aptose Management and KOL’s Discuss Early Clinical Observations with CG-806 and APTO-253
SAN DIEGO and TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting th...
SAN DIEGO and TORONTO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target ...
SAN DIEGO and TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target ...
Aptose Biosciences, Inc. (APTO) CEO William Rice on Q3 2019 Results - Earnings Call Transcript
SAN DIEGO and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiat...
SAN DIEGO and TORONTO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentia...
Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2019 Results - Earnings Call Transcript
About APTO
Aptose Biosciences, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clin... [Read more...]
| Industry Biotechnology | Founded 1986 |
| CEO William Rice | Employees 31 |
| Stock Exchange NASDAQ | Ticker Symbol APTO |
Analyst Forecasts
According to 8 analysts, the average rating for APTO stock is "Buy." The 12-month stock price forecast is 4.72, which is an increase of 7.27% from the latest price.